Company Overview and News
WASHINGTON: Private-sector hiring remained robust in June but slowed slightly from May's pace, payrolls firm ADP said in a monthly report on Thursday (Jul 5).
Private-sector hiring remained robust in June but slowed slightly from May's pace, payrolls firm ADP said in a monthly report Thursday.
There may be a bit of a more muted expectations for Friday’s key payrolls and unemployment report from the U.S. Department of Labor. The private sector payrolls report from ADP has set the tone here, although investors and employers should strongly consider that ADP uses its own data and the Labor Department data pertains to a sample from the entire U.S. labor force.
Texas Instruments (TXN - Free Report) , a Zacks Rank #1 (Strong Buy) designs and manufactures semiconductor solutions for analog and digital embedded and application processing. It has two major segments: Analog & Embedded Processing. The Analog segment semiconductors change real-world signals such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors.
ELY TXN ADP BGSF
WASHINGTON (Reuters) - U.S. economic growth slowed slightly more than initially thought in the first quarter amid downward revisions to inventory investment and consumer spending, but a robust labor market and income tax cuts are likely to boost activity this year.
Global bond markets calmed down on Wednesday, as investors paused for breath and continued to monitor the political crisis in Italy.
The euro rallied on Wednesday, rebounding from a more-than 10-month low as traders monitored the political situation in Italy, where reports said populist parties are making a last-ditch push to form a government.
The jobs report plays an important role in market movement. After a weaker improvement in March, the labor market was expected to see some improvements in April. The ADP employment report and the US non-farm payroll report for April were released on May 2 and May 4, respectively.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
The numbers: Private-sector employment stayed strong in April, as employers added 204,000 jobs, Automatic Data Processing Inc. reported Wednesday. That gain was above forecasts from economists polled by Econoday, who had expected on average an increase of 190,000. March’s gain was downwardly revised to show 228,000 growth instead of a previously estimated 241,000.
ADPVV ADP ADP
U.S. private sector employers made robust job additions in March, per a Automatic Data Processing Inc. ("ADP") and Moody’s Analytics report dated Apr 4. In fact, data from the same proved that the negative market sentiment about U.S. tariffs imposed on steel and aluminum by President Trump was overblown. Also, the U.S. Labor Department’s report released on Mar 9 showed that the economy added 313,000 jobs in February 2018, exceeding the consensus estimate of 208,000.
VEC GFN GFNCP DYNC ADP ADP DYN.WS DYN GFNSL ACIIQ ACI ADPVV VIRT DYN.WSA DYN-A ARCH GFDV DYN.PRA
The Dayton Power & Light J.M. Stuart Station lights up the early morning sky on the banks of the Ohio River in Aberdeen, Ohio, US, September 13, 2017. — Reuters picWASHINGTON, April 4 — US services sector activity slowed in March, held down by a drop in new orders, while private employers maintained a brisk pace of hiring.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to EPA:ADP / ADP on message board site Silicon Investor.